


**Supplementary Figure 1: Gating for IELp.**
Representative flow cytometry gating strategy for type A and type B IELp. Signaled DN thymocytes identified by the expression of CD5 and TCRβ, after excluding PBS57-CD1d tetramer$^{+}$, CD25$^{+}$, CD4$^{+}$, and CD8$^{+}$. Mature IELp were identified by CD122$^{+}$H-2K$^{b+}$. Type A IELp identified as PD-1$^{+}$ and Type B as NK1.1$^{+}$. Numbers adjacent to the outlined areas indicate the percentage of cells in each.




**Supplementary Figure 2: Gating for thymic APC.**
Representative flow cytometry gating strategy for thymic hAPC. Top panels show gating for B cells and dendritic cells: pDC, XCR1$^+$ cDC, and SIRP$\alpha^+$ cDC. Bottom panels show gating for myeloid populations: neutrophils, eosinophils, Ly6C$^-$ mononuclear phagocytes (MNP, which include both macrophages and monocytes) and Ly6C$^+$ monocytes. Numbers adjacent to the outlined areas indicate the percentage of cells in each.




**Supplementary Figure 3: Tissue specific deletion of MHC class I using *B2m*$^{fl/fl}$.** **(A)** Representative expression of H2-K$^{b}$, a classical MHCI molecule, on thymic APC in *Zbtb46*$^{Cre}$ (zDC$^{Cre}$)-*B2m*$^{fl/fl}$ mice (blue) and *B2m*$^{fl/fl}$ littermate controls (black). **(B)** Representative expression of H2-K$^{b}$ on thymic APC in *Itgax*$^{Cre}$ (CD11c$^{Cre}$)-*B2m*$^{fl/fl}$ mice (orange), *Lysm*$^{Cre}$-*B2m*$^{fl/fl}$ mice (purple), *Cd79a*$^{Cre}$ (Mb1$^{Cre}$)-*B2m*$^{fl/fl}$ mice (red), and *B2m*$^{fl/fl}$ littermate controls (black). For (A) and (B) mean fluorescence intensity is listed with littermate controls listed on top (black) and experimental mice on bottom (specified color above).




**Supplementary Figure 4: No hematopoietic APC subset is dedicated to Type B IELp selection.**

**(A)** Absolute number of Type B IELp in *Itgax*$^{Cre}$ (CD11c$^{Cre}$)-*B2m*$^{fl/fl}$ and littermate controls. Data are pooled from 4 independent experiments. **(B)** Absolute number of Type B IELp in *Lysm*$^{Cre}$-*B2m*$^{fl/fl}$ mice and littermate controls. Data are pooled from 3 independent experiments. **(C)** Absolute number of Type B IELp in *Clec4c* (BDCA2)-DTR$^{+/-}$ mice and littermate controls after a 9d course of DT treatment. Data are pooled from 4 independent experiments. **(D)** Absolute number of Type B IELp in WT mice treated with αIL-5 (clone TRFK5) or an IgG1 isotype control for 7d. Data are pooled from 3 independent experiments. **(E)** Absolute number of Type B IELp in *Cd79a*$^{Cre}$ (Mb1$^{Cre}$)-*B2m*$^{fl/fl}$ and littermate controls. Data are pooled from 5 independent experiments **(F)** Absolute number of Type B IELp *Itgax*$^{Cre}$x*Cd79a*$^{Cre}$-*B2m*$^{fl/fl}$ and littermate controls (right). Data are pooled from 3 independent experiments. For (A – F), the graph titles indicate the thymic APC populations affected in the experimental mice (Cre$^{+}$, BDCA2 DTR$^{+}$, αIL-5 treated). Each symbol represents an individual mouse. Error bars show mean ± SD. *ns* = not significant, unpaired two-tailed *t* test.